Yes, Biotime is mapping the embryome. Please, just the facts:
ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 4, 2013-- BioTime, Inc. (NYSE MKT: BTX) and subsidiary, LifeMap Sciences, announced that BioTime's CEO, Dr. Michael West will lead a session titled "From Mapping the Genome to Mapping the Embryome: The Urgent Need for an International Initiative" today at the 2013 World Stem Cell Summit in San Diego, California. The session will include world leaders in stem cell biology discussing how major advances in stem cell science and human health could be achieved by databasing the cellular components of the human body. In addition to Dr. West, Dr. Ronit Shtrichman, Technical Vice President of BioTime's Israeli subsidiary LifeMap Sciences Ltd., will give a presentation titled "LifeMap DiscoveryTM: An online database, integrating molecular and cellular information on embryonic development to improve stem cell research." LifeMap DiscoveryTM is a novel platform that links embryology, molecular and stem cell research in one location and is currently available to scientists worldwide
Baby Boom generation coming, PanCx on the market by end of next year being used in the top hospitals in the country like our partner Cornell Weill in NYC. Profits on this product alone will put us in the $100 range.
Sangamo's sister company Ceregene delivery ip:
Our AAV-based gene delivery technology provides a broad platform to develop pioneering treatments for many different serious diseases, including Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, Huntington’s disease and several ocular diseases. We are currently employing this technology in our human clinical trials for Parkinson’s disease and Alzheimer’s disease.